Kenji Tamura

Active 1986–2025

122
Papers
19,939
Citations
66
h-index
120
i10-index

Citations

Citations per year for Kenji Tamura1988: 1 citations1989: 2 citations1990: 5 citations1991: 2 citations1992: 3 citations1993: 1 citations1994: 4 citations1995: 1 citations1996: 2 citations1997: 2 citations1998: 2 citations1999: 9 citations2000: 2 citations2001: 7 citations2002: 11 citations2003: 2 citations2004: 5 citations2005: 11 citations2006: 11 citations2007: 24 citations2008: 26 citations2009: 43 citations2010: 39 citations2011: 27 citations2012: 28 citations2013: 43 citations2014: 48 citations2015: 94 citations2016: 126 citations2017: 129 citations2018: 144 citations2019: 690 citations2020: 1,048 citations2021: 1,229 citations2022: 1,211 citations2023: 954 citations2024: 1,301 citations2025: 557 citations2026: 9 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,257 citing papers, 19.9% of this breakdownChina: 1,479 citing papers, 13.1% of this breakdownJapan: 954 citing papers, 8.4% of this breakdownItaly: 745 citing papers, 6.6% of this breakdownUnited Kingdom: 585 citing papers, 5.2% of this breakdownGermany: 460 citing papers, 4.1% of this breakdownFrance: 443 citing papers, 3.9% of this breakdownSpain: 436 citing papers, 3.9% of this breakdownCanada: 329 citing papers, 2.9% of this breakdownAustralia: 299 citing papers, 2.6% of this breakdownSouth Korea: 269 citing papers, 2.4% of this breakdownNetherlands: 190 citing papers, 1.7% of this breakdown
0%19.9%Other 25.3%

Fields

  • Medicine63.9%
  • Biochemistry, Genetics and Molecular Biology27.3%
  • Immunology and Microbiology2.7%
  • Environmental Science1.2%
  • Neuroscience1%
  • Computer Science0.8%
  • Other3.1%

Topics

  • HER2/EGFR in Cancer Research6.8%
  • Cancer Immunotherapy and Biomarkers4.4%
  • PARP inhibition in cancer therapy4%
  • Advanced Breast Cancer Therapies3.8%
  • MicroRNA in disease regulation3.4%
  • Monoclonal and Polyclonal Antibodies Research3.1%
  • Other74.5%

Coauthors

All papers

Open in search
  1. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 1,973

  2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  3. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 817

  4. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 501

  5. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 493

  6. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier

    Authors: , , , , , , , , - Nature Communications 2015 cited by 710

  7. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , - Cancer Discovery 2020 cited by 353

  8. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2018 cited by 631

  9. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  10. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells

    Authors: , , , , , , , , , - Science Signaling 2014 cited by 703

  11. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 cited by 378

  12. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 cited by 350

  13. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 154

  14. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

    Authors: , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 108

  15. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

    Authors: , , , , , , , , , , , , , , - The Lancet Oncology 2019 cited by 229

  16. Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chitose Ogawa, Noriko Tanabe, Kokichi Sugano, Nobuyoshi Hiraoka, Kenji Tamura, Teruhiko Yoshida, Yasuhiro Fujiwara, Atsushi Ochiai, Noboru Yamamoto, Takashi Kohno - Cancer Science 2019 cited by 377

  17. First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

    Authors: , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 99

  18. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

    Authors: , , , , , , , , , , , , , , - BMC Cancer 2019 cited by 221

  19. Baseline Profile of Participants in the Japan Environment and Children’s Study (JECS)

    Authors: , , , , , , , , , , , , , - Journal of Epidemiology 2017 cited by 597

  20. Novel combination of serum microRNA for detecting breast cancer in the early stage

    Authors: , , , , , , , , , , , , , - Cancer Science 2016 cited by 363

  21. 64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2013 cited by 295

  22. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 107

  23. Insights Into Breast Cancer in the East vs the West

    Authors: , , , , , , , , , , - JAMA Oncology 2019 cited by 186

  24. Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1

    Authors: , , , , , , , , , - Nature Communications 2015 cited by 156